We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

Back to rankings

54 hedge funds and large institutions have $190M invested in Strongbridge Biopharma plc. in 2017 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 5

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

26% more funds holding

Funds holding: 43 → 54 (+11)

20% more capital invested

Capital invested by funds: $158M → $190M (+$32M)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
54
Holders Change
+11
Holders Change %
+25.58%
% of All Funds
1.22%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
16
Increased
22
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$7.34M
2
LSC
Lyon Street Capital
California
+$6.19M
3
BlackRock
BlackRock
New York
+$3.27M
4
SCM
Stonepine Capital Management
Oregon
+$2.15M
5
BC
Broadfin Capital
New York
+$1.87M

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$5.91M
2
VC
Vivo Capital
California
-$3.19M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$117K
4
CS
Credit Suisse
Switzerland
-$99K
5
NFA
Nationwide Fund Advisors
Ohio
-$83K
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
1
Caxton Corporation
New Jersey
$40M – – –
NMC
2
NEA Management Company
Maryland
$30M – – –
BC
3
Broadfin Capital
New York
$23.1M +$1.87M +299,900 +10%
AC
4
Armistice Capital
New York
$20.8M +$7.34M +1,175,400 +69%
VC
5
Vivo Capital
California
$17.8M -$3.19M -510,248 -17%
BlackRock
6
BlackRock
New York
$10.4M +$3.27M +522,875 +57%
LSC
7
Lyon Street Capital
California
$10.2M +$6.19M +991,322 +239%
OM
8
Opaleye Management
Massachusetts
$9.06M +$437K +70,000 +6%
TAF
9
Tredje AP-fonden
Sweden
$6.27M – – –
GPCM
10
Granite Point Capital Management
Massachusetts
$4.12M – – –
SCM
11
Stonepine Capital Management
Oregon
$2.5M +$2.15M +344,282 New
PA
12
Perceptive Advisors
New York
$1.99M +$1.72M +275,000 New
Hudson Bay Capital Management
13
Hudson Bay Capital Management
Connecticut
$1.81M +$1.56M +250,000 New
Northern Trust
14
Northern Trust
Illinois
$1.66M +$152K +24,281 +12%
6CM
15
683 Capital Management
New York
$1.45M +$1.25M +200,000 New
ZIM
16
Zacks Investment Management
Illinois
$1.43M +$1.23M +197,430 New
State Street
17
State Street
Massachusetts
$1.4M +$529K +84,666 +78%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$573K +$84.7K +13,554 +21%
Vanguard Group
19
Vanguard Group
Pennsylvania
$555K +$67.7K +10,837 +16%
Morgan Stanley
20
Morgan Stanley
New York
$520K +$271K +43,448 +154%
TCIM
21
TIAA CREF Investment Management
New York
$438K +$4.98K +797 +1%
Deutsche Bank
22
Deutsche Bank
Germany
$403K +$226K +36,160 +185%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$351K +$15K +2,398 +5%
Charles Schwab
24
Charles Schwab
California
$337K – – –
Wells Fargo
25
Wells Fargo
California
$324K +$256K +41,012 +1,130%
1
2 3

SBBP Hedge Fund Activity: Q4 2017 in Review

54 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2017, worth a combined $190M — up 20% from $158M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new SBBP positions and 5 closed out — a net gain of 11 holders — while 22 added to existing stakes and 5 trimmed.

The largest buyer was Armistice Capital, adding an estimated $7.34M. The largest seller was Boxer Capital, exiting entirely with an estimated $5.91M sold.

  • 54 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2017, up from 43 in Q3 2017.
  • Funds reported $190M of Strongbridge Biopharma plc. stock for Q4 2017, up 20% quarter-over-quarter.
  • 16 funds opened new Strongbridge Biopharma plc. positions in Q4 2017 and 5 closed out, a net change of +11 holders.
  • The largest Strongbridge Biopharma plc. buyer in Q4 2017 was Armistice Capital, an estimated $7.34M added.
  • The largest Strongbridge Biopharma plc. seller in Q4 2017 was Boxer Capital, an estimated $5.91M sold.

Based on aggregated 13F filings for Q4 2017.